Global Psoriatic Arthritis Pipeline 2016 Review in New Market Report

Jun 29, 2016, 22:00 ET from ReportsnReports

PUNE, India, June 30, 2016 /PRNewswire/ -- adds "Psoriatic Arthritis - Pipeline Review, H1 2016" market research report complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis and special features on late-stage and discontinued projects.

Complete report on H1 2016 pipeline review of Psoriatic Arthritis with 56 market data tables and 14 figures, spread across 252 pages is available at

The report also reviews key players involved in the therapeutic development for Psoriatic Arthritis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Psoriatic Arthritis Pipeline Review, H1 2016 report include AbbVie Inc., AbGenomics International, Inc., Alder Biopharmaceuticals Inc., Alteogen Inc., Amgen Inc., AstraZeneca Plc, BIOCAD, Biocon Limited, Bionovis SA, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Inc., Coherus BioSciences, Inc., Eli Lilly and Company, Epirus Biopharmaceuticals, Inc., Forward Pharma A/S, Genor BioPharma Co., Ltd., Innovent Biologics, Inc., Johnson & Johnson, Kadmon Corporation, LLC, Kineta, Inc., Mabion SA, Momenta Pharmaceuticals, Inc., Morphotek, Inc., Mycenax Biotech Inc., Novo Nordisk A/S, Oncobiologics, Inc., Panacea Biotec Limited, Pfizer Inc., Sandoz International GmbH, Swedish Orphan Biovitrum AB, Therapeutic Proteins International, LLC, UCB S.A., Valeant Pharmaceuticals International, Inc., Vitae Pharmaceuticals, Inc. and Xbrane Biopharma AB.

Drug profiles mentioned in this research report are abatacept, AbGn-168H, AbGn-168H2, ABT-122, adalimumab biosimilar, anakinra (recombinant), apremilast, bimekizumab, brodalumab, certolizumab pegol biosimilar, clazakizumab, COVA-322, dalazatide, dimethyl fumarate, DNX-114, etanercept, etanercept biosimilar, golimumab, golimumab biosimilar, guselkumab, infliximab biosimilar, INV-17, itolizumab, ixekizumab, KANAb-071, KD-025, liraglutide (recombinant), risankizumab, tofacitinib citrate, ustekinumab biosimilar, VALBRO-03 and VTP-43742.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis and reviews pipeline therapeutics for Psoriatic Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Psoriatic Arthritis therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Psoriatic Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Psoriatic Arthritis.

Order a copy of Psoriatic Arthritis - Pipeline Review, H1 2016 market research report @

Reasons to buy: Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies; Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage; Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis; Identify potential new clients or partners in the target demographic; Develop strategic initiatives by understanding the focus areas of leading companies; Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics; Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics; Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope; Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Another newly published market research report titled on Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2016 talks about companies like Alvogen Korea Co., Ltd., AnGes MG, Inc., AstraZeneca Plc, Athersys, Inc., Bayer AG, Betagenon AB, CardioVascular BioTherapeutics, Inc., Celgene Corporation, Hemostemix Ltd, ID Pharma Co., Ltd., Juventas Therapeutics, Inc., miRagen Therapeutics, Inc., Multi Gene Vascular Systems Ltd, Nuo Therapeutics, Inc., Proteon Therapeutics, Inc., Recardio GmbH, Resverlogix Corp., Sigma-Tau S.p.A., Stemedica Cell Technologies, Inc., Symic Biomedical, Inc., Theravasc, Inc., ViroMed Co., Ltd. and Yuyu Pharma, Inc. Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Pipeline market research report of 180 pages is available at

Explore more reports on Pharmaceuticals.

About Us: is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:




G+ / Google Plus:


Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+1 888 391 5441

SOURCE ReportsnReports